GlassScriptPhysician profile
Brian W Buoscio
NPI 1912994534
$14,680.07
in general payments reported to CMS, 2019-2025
53 companies · $32.88 in 2025
The $32.88 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,634 · 2020: $1,415 · 2021: $2,221 · 2022: $2,530 · 2023: $2,991 · 2024: $2,856 · 2025: $32.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,879.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,675.13 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,519.65 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,216.49 | 2019-2024 | Farxiga, Airsupra, Fasenra |
| Amgen INC. | $1,129.64 | 2019-2024 | Evenity, Prolia, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $987.00 | 2021-2024 | |
| Glaxosmithkline, LLC. | $939.63 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $939.54 | 2019-2024 | Ozempic, Rybelsus |
| Pfizer INC. | $905.99 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $761.99 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $428.50 | 2019-2024 | Belsomra, Steglatro, Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $413.22 | 2019-2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $388.33 | 2019-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $325.58 | 2019-2023 | |
| Abbott Laboratories | $275.60 | 2021-2024 | Freestyle Libre 3 |
| Nestle Healthcare Nutrition INC. | $253.34 | 2021-2023 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Buoscio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.